Investment Pitches

Pitch Summary:
Swiss biopharmaceutical and diagnostics company Roche reported positive Phase III data in the fourth quarter for giredestrant in breast cancer and fenebrutinib in multiple sclerosis, paving the way for new treatments with peak sales opportunities of $5 billion each. These two products should enable Roche to grow revenues through the loss of exclusivity period for several cancer and MS drugs and secure its place among the pharmaceutical companies that can grow revenue for the next 10+ years.

BSD Analysis:
Roche is one of the last true research-driven pharma giants, and it shows in both the strengths and frustrations of the stock. Diagnostics give Roche a cash-generative backbone that most pharma companies would love to have, smoothing the inevitable drug-cycle volatility. Oncology remains the core franchise, even as legacy blockbusters age out. The pipeline is broad, but Roche’s challenge is speed — execution matters more than scientific ambition right now. Margins remain resilient because diagnostics and biologics carry pricing power. The balance sheet is rock-solid, buying management time that competitors often don’t have. Roche rarely wins on hype, but it wins on persistence. This is a long-duration compounder built for decades, not quarters. Investors need patience, but patience has historically been rewarded.

Pitch Summary:
U.K.-based NatWest Group was a leading contributor during the quarter, and we think banks can continue to work as we believe that interest rates will be stable and loan growth will likely increase along with higher fiscal stimulus and to fund AI and energy transitions. Those new loans will be more profitable with stable credit quality. Bank valuations remain inexpensive with excess capital and strong cash generation supporting high dividends.

BSD Analysis:
NatWest is a domestic UK bank benefiting from normalized interest rates after a decade of repression. Capital levels are strong enough to support buybacks and dividends without balance-sheet gymnastics. Credit quality has held up better than headline macro fear suggests. Investors punish UK exposure reflexively, keeping valuations compressed. Cost control and simplification efforts are steadily improving returns. Loan growth is modest, but profitability doesn’t require expansion. Regulatory risk exists, but it’s well understood and largely priced in. NatWest is no longer a recovery story — it’s an earnings yield story. In banking, boring plus capital discipline tends to work.

Pitch Summary:
U.K. biopharmaceutical maker AstraZeneca was a bright spot in the pharmaceutical side of health care. While health care stocks have been weak overall, we view AstraZeneca as benefiting from moderating U.S. pricing pressures and improving visibility following policy uncertainty. The company continues to execute well across its late-stage pipeline and remains positioned to deliver sustainable revenue growth despite sector-wide headwinds.

BSD Analysis:
AstraZeneca has quietly built one of the deepest large-cap pharma pipelines, anchored by oncology and rare disease franchises that actually move the needle. Growth is driven by volume and innovation rather than price inflation optics, which matters politically. The post-COVID hangover distorted sentiment, but core drugs continue to gain share globally. Emerging markets add durability that peers often lack. Investors worry about patent cliffs, yet the pipeline breadth meaningfully reduces single-asset risk. R&D productivity has been consistently strong, not episodic. Margin expansion comes from scale and mix, not financial engineering. AstraZeneca doesn’t need heroic M&A to grow. This is pharma execution compounding while the market looks elsewhere.

Pitch Summary:
We also exited our position in payments company PayPal. While we had thought that stronger leadership could help reaccelerate growth within PayPal’s core franchise, performance has suggested that this may be a more daunting task than we anticipated given the company’s exposure to structurally slower growth areas of e-commerce. With a growing probability that the company could fail to break out from mid-single-digit growth rates for the foreseeable future, we decided to sell the stock.

BSD Analysis:
PayPal is a former growth darling now living in self-help territory, which is exactly why it’s interesting again. The core franchise is still massive — hundreds of millions of active users, global merchant acceptance, and brand trust that most fintechs would kill for. The problem was never relevance; it was bloated costs, scattered product strategy, and complacency. New management is stripping that out, refocusing on branded checkout, margin discipline, and monetizing the user base instead of just counting it. Venmo remains under-monetized relative to its engagement, and that optionality is real if execution improves. Competition from Apple Pay, Stripe, and wallets is intense, but PayPal still owns distribution at checkout in a way challengers struggle to replicate. Free cash flow is strong, giving PayPal room to buy back stock aggressively while it fixes the business. This is no longer a growth story — it’s a repair-and-rerate story. If management delivers even modest execution gains, the upside from today’s depressed expectations is meaningful.

Pitch Summary:
In the fourth quarter, we made several changes within our financials holdings. For example, we swapped our exposure within regional banks by replacing M&T Bank with Fifth Third Bancorp. We believe that Fifth Third is poised to accelerate its growth by combining its best-in-class digital strengths with recently acquired Comerica’s middle-market franchise in fast-growing, attractive regions in the Southeast, Texas and California, ultimately upgrading our overall return profile.

BSD Analysis:
Fifth Third is a disciplined regional bank that survives by not doing stupid things — an underrated strategy in banking. Its Midwest footprint provides stable deposits and diversified lending exposure. Credit quality has historically held up because underwriting matters more than growth targets. Fee income and payments exposure add ballast when net interest margins compress. Rising rates helped, normalization will hurt, and that’s already understood by the market. Capital levels are solid, supporting dividends and buybacks. This is not a bank that swings for the fences. It compounds quietly while others blow themselves up. In regional banking, boring is alpha.

Pitch Summary:
Simpson Manufacturing is a leading building products company focused on connectors, truss plates and fasteners used in residential construction. The company holds a dominant share in its core categories, supported by strong brand recognition and deep relationships with builders. Attractive margins and a disciplined operating model have enabled consistent profitability through housing cycles. Management sees opportunities to expand into adjacent product categories and gain share internationally. We view Simpson as a steady compounder capable of delivering durable growth over time.

BSD Analysis:
Simpson Manufacturing owns a brutally unsexy but incredibly powerful niche: structural connectors that keep buildings standing. Its products are embedded in building codes, engineering specs, and contractor habits, which is about as sticky as it gets. Even when housing slows, repair, retrofit, and code-driven demand keep volumes from collapsing. Simpson has real pricing power because failure is not an option in structural integrity. Margins reflect manufacturing discipline, not promotional games. The balance sheet is clean, giving flexibility through cycles. This business doesn’t chase growth — it inherits it through regulation and safety standards. The stock often trades like a housing cyclical, but the business behaves more defensively. This is infrastructure hiding inside residential construction.

Pitch Summary:
Protagonist Therapeutics is a biopharmaceutical company that currently has two internally discovered, clinically derisked drugs likely to launch with their partners in the near future, which we believe offer blockbuster potential — particularly an oral version of a well-adopted injectable mechanism treating a range of immunology and inflammation conditions. The company’s pipeline is differentiated by its oral delivery approach, which could significantly improve patient adherence versus injectable alternatives. Both programs have been validated through prior clinical data, reducing development risk. The proximity to commercialization with partners improves capital efficiency and downside protection. We believe upcoming launches represent meaningful value creation opportunities for shareholders.

BSD Analysis:
Protagonist is a biotech that looks boring until you understand how differentiated its peptide platform really is. The company targets well-validated biology with novel delivery approaches, reducing binary risk compared to moonshot science. Partnerships help validate assets and offset funding risk. Clinical results matter enormously — valuation moves with data, not sentiment. The upside is asymmetric if lead programs continue to hit, especially in large autoimmune indications. Timelines are long and volatility is guaranteed. This is not a revenue story yet — it’s an evidence story. For disciplined biotech exposure, Protagonist offers real science with measured ambition. High risk, but not reckless.

Pitch Summary:
We recently initiated a position in Molina Healthcare (MOH), which we believe is a mispriced compounder experiencing transitory margin pressure. The stock traded as high as $300 per share only six months ago; we purchased our shares at approximately $160 in late December. Molina provides managed healthcare services primarily to low-income families and individuals via Medicaid, Medicare and the various state marketplaces established by the 2010 Affordable Care Act (Obamacare). The company is an example of a situation in which the stock price decline has been vastly exacerbated by negative political news—and mostly disconnected from the company’s actual business fundamentals. In our view, the market’s reaction extrapolates short-term pressures indefinitely and underappreciates both the structural dynamics of Medicaid rate resets and Molina’s long track record of operational outperformance versus peers. We see a credible path to 2–3x upside over the next several years as margins normalize and earnings power becomes evident.

BSD Analysis:
Molina is a focused Medicaid insurer benefiting from scale and cost discipline. Government programs provide volume stability even in downturns. Margin swings reflect state-level reimbursement dynamics. Investors fear policy risk reflexively. Yet Medicaid enrollment remains structurally elevated. Operational execution has improved materially. Cash flow supports balance sheet strength. Molina doesn’t need multiple expansion to work. This is public healthcare executed privately.

Pitch Summary:
IntegraFin released full-year results to September 2025, reporting a 16% increase in funds under direction following strong net inflows of £4.4 billion. Platform clients increased by 5% to over 246,000 during the year, reflecting continued adviser adoption of the Transact platform. The shares rose 3.8% over the quarter as investors welcomed the steady growth in assets and client numbers.

BSD Analysis:
IntegraFin operates an investment platform embedded in adviser workflows. Switching costs are meaningful once assets sit on-platform. Market volatility affects flows, not relevance. Fee pressure exists but scale offsets it. Investors trade sentiment around AUM swings. Advisors value stability over novelty. Cash flow remains strong. This is financial infrastructure with cyclical optics. Plumbing beats products.

Pitch Summary:
AJ Bell recorded £7.5 billion of net inflows and delivered 18% revenue growth in the year to 30 September. However, its shares fell 18% over the quarter as management committed to accelerating investment in brand and marketing. This raised concerns among investors that higher spending could put pressure on operating margins in the year ahead. The market reaction reflected sensitivity to margin dilution despite continued strong top-line momentum.

BSD Analysis:
AJ Bell is a UK retail investment platform whose moat is low-cost positioning paired with operational reliability rather than product flash. The business benefits structurally from the shift toward self-directed investing and platform consolidation. Assets under administration drive revenue, making markets—not flows—the primary short-term earnings lever. Pricing power is limited by competition, but cost discipline and scale offset that constraint. Customer stickiness is decent, though not immune if performance or service slips. Regulatory changes are a constant background risk but also a barrier to entry. The bull case is steady long-term AUA growth with operating leverage as scale improves. The bear case is prolonged weak markets compressing revenue while fixed costs linger. AJ Bell compounds quietly when markets cooperate—and survives when they don’t.

Pitch Summary:
Big Technologies was one of the portfolio’s strongest performers, rising 24% during the quarter. The company reported a number of positive developments in underlying trading despite the absence of updates on its ongoing litigation against its former founder and CEO. It secured new electronic monitoring business wins in Lithuania, Latvia and Pierce County in Washington State, alongside a new contract in Prince Edward Island, Canada. Big Technologies also announced a strategic partnership with US-based Recovery Monitoring Solutions to provide alcohol monitoring and GPS products. In addition, the company received US approval for a new product that combines alcohol detection, GPS tracking and facial recognition, expanding its addressable market.

BSD Analysis:
Big Technologies supplies electronic monitoring systems for justice and offender management. Government contracts are sticky and long duration. Ethical debates don’t remove demand. Switching costs are high due to data and security. Revenue visibility is strong once contracts are signed. Investors struggle with headline risk. Yet incarceration alternatives are expanding. Margins reflect software-plus-hardware economics. This is niche govtech with durability.

Pitch Summary:
One such example is Spectrum Brands. Spectrum Brands is a global consumer products company whose brands are found in millions of households, spanning pet care, home and garden, personal care, and household products. In recent years, results have been pressured by post-COVID normalization, retailer destocking, input cost inflation, and tariffs on Chinese imports, which compressed margins and earnings. Importantly, these challenges are viewed as cyclical rather than structural. The company has strengthened its balance sheet, reduced leverage, and is expected to generate roughly $150 million of free cash flow compared to an equity market capitalization of approximately $1.4 billion.

BSD Analysis:
Spectrum is a portfolio of household brands tied to everyday necessity rather than aspiration. Complexity and past missteps destroyed investor trust. Asset sales and simplification are slowly improving focus. Demand is resilient even when consumers trade down. Margins depend on execution, not branding magic. Investors assume perpetual dysfunction. If cost discipline holds, earnings stabilize quickly. This is a clean-up story with real products. Fix the house, then re-rate.

Pitch Summary:
Another example is Drax Group plc, a UK-based power generation company that plays an important but often overlooked role in Britain’s energy system. Drax provides dispatchable power, supplying roughly 6–7% of the UK’s electricity, which is critical as intermittent wind and solar generation increase. The company generates significant free cash flow and trades at a low valuation of approximately 6.5x earnings while offering a dividend yield of around 3.4%. Although government support for its power station is scheduled to end in 2031, the market assigns little value beyond that date. We believe this overlooks the long-term strategic value of Drax’s grid-connected assets and the potential to extend its life through long-term power contracts, including supplying electricity directly to data centres.

BSD Analysis:
Drax sits at the messy intersection of energy transition, politics, and legacy assets. Biomass subsidies dominate the narrative and valuation. Power generation remains strategically important for UK grid stability. Carbon policy risk is real and binary. Investors price Drax for political disappointment. Cash flows exist but are policy-dependent. Capital allocation choices matter enormously. This is not a clean ESG story. It’s a political risk asset masquerading as green power.

Pitch Summary:
One such example is Jamieson Wellness. Jamieson Wellness is one of Canada’s leading producers of vitamins, minerals, and nutritional supplements. If you have ever walked down the supplement aisle of a pharmacy, grocery store, or big-box retailer, you have likely seen Jamieson products. The company sells branded vitamins such as vitamin D, multivitamins, probiotics, and immune-support products that consumers buy repeatedly as part of daily health routines. Jamieson’s business is simple and durable, benefiting from strong brand recognition built over more than a century. Importantly, Jamieson is not just a Canadian story, having doubled revenue and EBITDA over the last five years through international expansion, with the U.S. and China now accounting for nearly half of its business.

BSD Analysis:
Jamieson is a trusted consumer health brand benefiting from preventative wellness trends. Vitamins and supplements are habitual purchases, not impulse buys. Brand trust matters more than innovation hype. Margins reflect scale and sourcing discipline. Investors lump Jamieson with fad supplement names unfairly. Distribution expansion supports steady growth. Emerging markets add optionality. This is consumer healthcare, not lifestyle noise. Trust compounds slowly but powerfully.

Pitch Summary:
Galderma was among the top contributors, supported by strong operating momentum. Third quarter sales rose by more than 20%, taking nine-month sales to a record level. Management raised full-year guidance, citing broad-based traction and the ramp-up of key launches, including Nemluvio. Sentiment was further supported when L’Oréal announced an increased stake, which we view as external validation of Galderma’s long-term potential.

BSD Analysis:
Galderma operates in dermatology where aesthetics meet medicine. Demand is resilient and recurring. Brand trust matters enormously. Product pipelines extend lifecycle value. Margins benefit from premium positioning. Investors underappreciate procedural stickiness. Growth doesn’t rely on reimbursement cycles. This is medical consumerism. Beauty with barriers.

Pitch Summary:
DSV was a top contributor as third quarter revenue rose 63% year-on-year and EBIT increased 23%, aided by the Schenker acquisition. Management highlighted accelerated integration progress and early evidence of customer retention. While organic demand remained mixed and margins eased, the company tightened full-year guidance and reiterated confidence in delivering substantial synergies over time. DSV’s operational discipline, scale advantages and integration capability remain central to our long-term thesis.

BSD Analysis:
DSV is an asset-light logistics compounder whose real moat is execution discipline in an industry that routinely destroys value. Freight forwarding looks interchangeable until customers experience disruption—then reliability beats price every time. Scale matters because it buys purchasing power with carriers and resilience during volume swings. M&A is the growth engine, but integration skill is the differentiator; DSV has proven unusually good at extracting synergies without blowing up culture. Earnings are cyclical because global trade is cyclical, no matter how “variable cost” the model claims to be. When volumes fall, operating leverage still bites. The bull case is continued industry consolidation with DSV as the most credible buyer. The bear case is a prolonged trade downturn exposing how thin logistics margins really are. DSV compounds by being relentlessly competent in a structurally unforgiving business.

Pitch Summary:
Advantest was among the top contributors during the quarter. Results exceeded expectations, with management meaningfully raising guidance, citing sustained demand tied to artificial intelligence data center investment and improved visibility. Held since the second quarter of 2024, Advantest has benefited from its mission-critical role in advanced semiconductor testing and deep customer relationships. These attributes should support attractive growth as semiconductor complexity continues to rise.

BSD Analysis:
Advantest supplies testing equipment critical to advanced chips. AI increases test complexity and intensity. Cycles delay orders but expand long-term demand. Customer relationships are sticky. Margins reflect IP depth. Investors trade capex sentiment. Testing is non-negotiable. This is bottleneck exposure. Complexity pays.

Pitch Summary:
Ferrari shares fell after its Capital Markets Day, where 2030 targets and electrification messaging underwhelmed the market. This occurred despite Ferrari’s long record of prudent guidance and strong execution. Ferrari remains defined by scarcity and exceptional pricing power, and it has been a top contributor to the Fund’s long-term performance. We reduced the position during the year to better align position sizing with conviction. We remain confident in Ferrari’s long-term compounding potential underpinned by unrivalled brand equity and deliberate control of supply.

BSD Analysis:
Ferrari’s moat is engineered scarcity wrapped in cultural mythology, not horsepower or technology. The company sells aspiration first and vehicles second, which is why pricing power looks irrational and still works. Demand is curated, not maximized—Ferrari controls supply to protect brand equity even when it leaves money on the table. Margins are protected by customization, merchandising, and a client base that treats price increases as status signals. Electrification is a risk, but Ferrari’s customers buy identity, not drivetrains. The real threat is brand dilution through overexpansion, not competition from other supercars. The bull case is continued scarcity discipline with luxury pricing compounding faster than volumes. Ferrari is one of the few manufacturers that behaves like a luxury house—and gets paid like one.

Pitch Summary:
Sea Ltd. was a detractor despite strong operating performance. Third quarter results showed group revenues rising almost 40% year-on-year and adjusted EBITDA up 68%, led by Garena, where bookings grew 51% and profitability improved materially. Shopee delivered strong GMV and revenue growth, but profitability fell below expectations as management continued to invest in logistics and fulfilment. Shares were also sensitive to discussions of potential future Latin American expansion. We remain encouraged by strengthening fundamentals and management’s financial discipline as it invests to deepen long-term competitive advantages.

BSD Analysis:
Sea is a platform built in hard markets, where logistics, payments, and trust had to be created from scratch. Shopee’s moat is regional execution—local sellers, delivery, and consumer habits that outsiders underestimate. Profitability only appears when growth is restrained, which tests management discipline. Garena remains volatile but can still fund the ecosystem when hits land. SeaMoney adds stickiness, but credit risk rises exactly when growth looks strongest. The failure mode is familiar: reinvesting too early and reopening subsidy wars. The bull case is profitable regional dominance with real operating leverage. Sea wins only if it remembers the cost of its last growth binge.

Pitch Summary:
Spotify was a notable detractor during the quarter despite continued operating progress. Third quarter results showed users increasing 11% to 713 million and subscribers growing 12% to 281 million, while operating income expanded to a mid-teens margin alongside record quarterly free cash flow. Shares weakened as investors reset near-term margin expectations. We remain confident that pricing, product innovation, advertising efficiency and an expanding ecosystem can continue to widen margins over time, reinforced this quarter by the launch of Spotify recommendations within ChatGPT.

BSD Analysis:
Spotify dominates global audio distribution, but dominance does not equal control over economics. The moat is scale, data, and personalization—users don’t churn easily once habits form. The weak point is structural: music labels own the content and cap margin expansion. Podcasts and audiobooks improve mix, but they require constant reinvestment and execution discipline. Pricing power exists at the margin, yet consumer sensitivity limits how fast ARPU can move. Operating leverage is real if cost growth stays contained. The bull case is steady margin expansion from ads and non-music content. Spotify is a category winner still negotiating with its own ceiling.